Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6828146 | 0.87 | GPR35 (0.52) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL27809236 | 0.86 | GPR35 (0.61) | GPR35ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL7028476 | 0.85 | ERN1 (0.56) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL11075976 | 0.84 | GPR35 (0.59) | GPR35ALDH1A1MAPTKMT2APOLB | |
| SCHEMBL4301550 | 0.84 | MEN1 (0.52) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL591200 | 0.84 | GPR35 (0.56) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL30098373 | 0.84 | GPR35 (0.56) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL505591 | 0.83 | PDGFRB (0.48) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL207052 | 0.83 | ERN1 (0.50) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL205671 | 0.83 | TTR (0.50) | GPR35PDGFRBFGFR1PDGFRAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-8263592-B2 | Equilibrative nucleoside transporter ENT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-8026235-B1 | Pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2011-09-27 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-04 | — | — | US | disclosed |
| WO-2009062990-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-22 | — | — | WO | disclosed |
| CN-1216851-C | Process for producing bis (4-hydroxy-3-nitrophenyl) compound | NIPPON KAYAKU KK (JP) | 2005-08-31 | — | — | CN | disclosed |
| CN-1426390-A | Process for producing bis (4-hydroxy-3-nitrophenyl) compound | NIPPON KAYAKU KK (JP) | 2003-06-25 | — | — | CN | disclosed |
| US-4442115-A | ANTI-ASTHMA | MAY & BAKER LIMITED (GB) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280025-A1 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | SLC29A1, SLC29A2, SLC43A3 | GPR35 1242/4885PDGFRB 3512/4885FGFR1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.